REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to ...
General Fusion's merger with an acquisition company will net the company over $300 million. Just last year, the company ran into trouble raising money from other investors.
In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and improved beta-cell function subsequent to the dosing period In a rodent model ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results